Advertisement

If you have an ACS member number, please enter it here so we can link this account to your membership. (optional)

ACS values your privacy. By submitting your information, you are gaining access to C&EN and subscribing to our weekly newsletter. We use the information you provide to make your reading experience better, and we will never sell your data to third party members.

ENJOY UNLIMITED ACCES TO C&EN

Business

Anadys, Adolor Restructure, Cut Jobs

by Rick Mullin
June 15, 2009 | A version of this story appeared in Volume 87, Issue 24

Anadys Pharmaceuticals announced a 40% workforce reduction through the elimination of 20 jobs. The firm says it will focus its drug development operations on its lead compound, ANA598, currently in Phase II studies in conjunction with pegylated interferon-alpha and ribavirin for hepatitis C. The company plans to suspend development of ANA773, currently in studies for hepatitis and oncology applications. The moves should generate annual savings of between $4 million and $5 million, Anadys says. Separately, biopharmaceutical firm Adolor says it will cut 45 positions, a 28% workforce reduction. The firm intends to shift its focus to clinical development programs and its first commercial product, Enterge, an agent to accelerate healing from upper gastrointestinal surgery. The move will reduce annual expenses by approximately $12 million, the firm says.

Article:

This article has been sent to the following recipient:

0 /1 FREE ARTICLES LEFT THIS MONTH Remaining
Chemistry matters. Join us to get the news you need.